Patent classifications
C07C271/18
FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES
There is described herein use of a compound of formula (I) below to make cyclic peptides.
##STR00001##
FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES
There is described herein use of a compound of formula (I) below to make cyclic peptides.
##STR00001##
Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.
Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.
Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.
SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION
The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.
SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION
The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.
Method for producing kakeromycin and derivatives thereof
Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1): ##STR00001##
wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2): ##STR00002##
wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.
Method for producing kakeromycin and derivatives thereof
Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1): ##STR00001##
wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2): ##STR00002##
wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.
Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation
The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.